CHARLES RIVER ACQUIRES DISTRIBUTED BIO
This acquisition allows us to offer an integrated, end-to-end platform for therapeutic antibody discovery and development.
WHAT WE DO
ABOUT US
We are computational immuno-engineers. Our mission is to create breakthrough technologies to drug previously challenging targets (GPCRs, ion channels, pMHC complexes, condition-specific binders, anti-idiotypes, and broadly neutralizing viral epitopes). In monoclonal therapeutics, our integration of computational immunology, bioengineering and robotics has enabled us to create a pipeline of molecules with unprecedented biophysical properties, while also supporting all of our partners with thousands of high affinity developable antibodies against any drug target of interest.
OUR
TECHNOLOGIES
SuperHuman
The world’s most advanced computationally optimized human antibody library for antibody discovery. Discover IgGs, CAR-Ts, bi-specific, and scFvs against any target using the SuperHuman synthetic antibody library.
Tungsten, AbGenesis and Tumbler
Quickly discover, analyze, and engineer therapeutic antibodies starting with a comprehensive antibody discovery platform and ending with an IND package. Work with a partner that offers an end-to-end solution, and give your therapeutic antibody the best chance for success.
Need amazing antibodies? Get in touch to help us discover your next therapeutic.